Systemic lupus erythematosus (SLE) can be a mysterious disease, presenting with extremely divergent clinical phenotypes. Already, biomarkers are very helpful tools for diagnosis, assessment and monitoring of disease activity, differential diagnosis of clinical manifestations, prediction of the disease course and stratified therapy, and they hold the key to personalized medicine in SLE. We summarize the clinical information that can only be supplied by autoantibodies, complement components and interferon biomarkers in this diverse disease.
HooksJJMoutsopoulosHMGeisSAStahlNIDeckerJLNotkinsAL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med1979; 301: 5–8.
2.
ShererYGorsteinAFritzlerMJShoenfeldY. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Sem Arthritis Rheum2004; 34: 501–537.
3.
Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Therapeutics2001; 69: 89–95.
4.
van VollenhovenRFPetriMACerveraR. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheu Dis2012; 71: 1343–1349.
5.
KalunianKCMerrillJTMaciucaR. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis2016; 75: 196–202.
6.
MorimotoAMFlesherDTYangJ. Association of endogenous anti-interferon-alpha autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum2011; 63: 2407–2415.
7.
YaoYHiggsBWRichmanLWhiteBJallalB. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus. Arthritis Res Ther2010; 12: S6–S6.
8.
HolborowEJWeirDMJohnsonGD. A serum factor in lupus erythematosus with affinity for tissue nuclei. Br Medical J1957; 2: 732–734.
9.
IsenbergDAMansonJJEhrensteinMRRahmanA. Fifty years of anti-ds DNA antibodies: are we approaching journey's end?Rheumatology (Oxford)2007; 46: 1052–1056.
10.
BrunsABlassSHausdorfGBurmesterGRHiepeF. Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum2000; 43: 2307–2315.
11.
AmouraZPietteJCBachJFKoutouzovS. The key role of nucleosomes in lupus. Arthritis Rheum1999; 42: 833–843.
12.
RubinRL. Drug-induced lupus. Expert Opinion Drug Safety2015; 14: 361–378.
13.
Araujo-FernandezSAhijon-LanaMIsenbergDA. Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced. Lupus2014; 23: 545–553.
14.
BiesenRDahnrichCRosemannA. Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus. Arthritis Res Ther2011; 13: R26–R26.
15.
BarkhudarovaFDahnrichCRosemannA. Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus. Arthritis Res Ther2011; 13: R20–R20.
16.
BizzaroNVillaltaDGiavarinaDTozzoliR. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev2012; 12: 97–106.
17.
SuerWDahnrichCSchlumbergerWStockerW. Autoantibodies in SLE but not in scleroderma react with protein-stripped nucleosomes. J Autoimmun2004; 22: 325–334.
18.
AlbaPBentoLCuadradoMJ. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis2003; 62: 556–560.
19.
MoroniGTrendelenburgMDel PapaN. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis2001; 37: 490–498.
20.
SiegertCEDahaMRTsengCMCoremansIEvan EsLABreedveldFC. Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis1993; 52: 851–856.
21.
TrendelenburgMMarfurtJGerberITyndallASchifferliJA. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum1999; 42: 187–188.
22.
ArnettFCReichlinM. Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P. Am J Med1995; 99: 465–472.
23.
OhiraHTakiguchiJRaiT. High frequency of anti-ribosomal P antibody in patients with systemic lupus erythematosus-associated hepatitis. Hepatol Res2004; 28: 137–139.
24.
SannaGBertolacciniMLCuadradoMJ. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol2003; 30: 985–992.
25.
HanlyJGUrowitzMBSiannisF. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum2008; 58: 843–853.
26.
LennonVAWingerchukDMKryzerTJ. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet2004; 364: 2106–2112.
27.
RoemerSFParisiJELennonVA. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain2007; 130: 1194–1205.
RoseTGrutzkauAHirselandH. IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis2013; 72: 1639–1645.
30.
ter BorgEJHorstGHummelEJLimburgPCKallenbergCG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum1990; 33: 634–343–634–343.
31.
BauerJWPetriMBatliwallaFM. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum2009; 60: 3098–3107.
32.
HoAMagderLSBarrSGPetriM. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum2001; 44: 2342–2349.
33.
ArbuckleMRMcClainMTRubertoneMV. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med2003; 349: 1526–1533.
34.
NgKPMansonJJRahmanAIsenbergDA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum2006; 55: 900–904.
35.
BootsmaHSpronkPDerksenR. Prevention of relapses in systemic lupus erythematosus. Lancet1995; 345: 1595–1599.
36.
TsengCEBuyonJPKimM. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum2006; 54: 3623–3632.
37.
AlexanderTSarfertRKlotscheJ. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis2015; 74: 1474–1478.
JacobiAMMeiHHoyerBF. HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis2010; 69: 305–308.
40.
OdendahlMJacobiAHansenA. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol2000; 165: 5970–5979.
41.
StohlWHiepeFLatinisKM. Belimumab reduces autoantibodies, normalizes low complement, and reduces select B-cell populations in patients with systemic lupus erythematosus. Arthritis Rheum2012; 64: 2328–2337.
42.
AlexanderTThielARosenO. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood2009; 113: 214–223.
43.
BelotACimazR. Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis. Pediat Rheumatol2012; 10: 21–21.
44.
KaoAHNavratilJSRuffingMJ. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum2010; 62: 837–844.
45.
LangeKWassermanESlobodyLB. The significance of serum complement levels for the diagnosis and prognosis of acute and subacute glomerulonephritis and lupus erythematosus disseminatus. Ann Internal Med1960; 53: 636–646.
46.
Hui-YuenJSReddyATaylorJ. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol2015; 42: 2288–2295.
47.
Costedoat-ChalumeauNAmouraZHulotJS. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum2006; 54: 3284–3290.
48.
BaechlerECBatliwallaFMKarypisG. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Nat Acad Sci USA2003; 100: 2610–2615.
49.
BennettLPaluckaAKArceE. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med2003; 197: 711–723.
50.
YaoYHiggsBWMorehouseC. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genom Proteom2009; 1: 374312–374312.
51.
HuaJKirouKLeeCCrowMK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum2006; 54: 1906–1916.
52.
BiesenRDemirCBarkhudarovaF. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum2008; 58: 1136–1145.
53.
LiYLeePYKellnerES. Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus. Arthritis Res Ther2010; 12: R90–R90.
54.
TrinchieriG. Type I interferon: friend or foe?J Exp Med2010; 207: 2053–2063.
55.
BaechlerECBatliwallaFMReedAM. Gene expression profiling in human autoimmunity. Immunol Rev2006; 210: 120–137.
56.
Peck-RadosavljevicMWichlasMHomoncik-KramlM. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology2002; 123: 141–151.
57.
BengtssonAASturfeltGTruedssonL. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus2000; 9: 664–671.
58.
FengXWuHGrossmanJM. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum2006; 54: 2951–2962.
59.
LuoNWuYChenY. Upregulated BclG(L) expression enhances apoptosis of peripheral blood CD4+ T lymphocytes in patients with systemic lupus erythematosus. Clin Immunol2009; 132: 349–361.
60.
ShiozawaSKurokiYKimMHirohataSOginoT. Interferon-alpha in lupus psychosis. Arthritis Rheum1992; 35: 417–422.
61.
Landolt-MarticorenaCBonventiGLubovichA. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis2009; 68: 1440–1446.
62.
PetriMSinghSTesfasyoneH. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus2009; 18: 980–989.
63.
KongKOTanAWThongBY. Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol2009; 156: 134–140.
64.
Kikuchi-TauraAYuraATsujiS. Monocyte CD64 expression as a novel biomarker for the disease activity of systemic lupus erythematosus. Lupus2015; 24: 1076–1080–1076–1080.
65.
KuznikABencinaMSvajgerUJerasMRozmanBJeralaR. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol2011; 186: 4794–4804.
